Physical characterization of liposomal drug formulations using multi-detector asymmetrical-flow field flow fractionation

JOURNAL OF CONTROLLED RELEASE

卷:320

Article

Parot, J.^1,2  Caputo, F.³  Mehn, D.⁴  Hackley, V. A.¹  Calzolai, L.⁴ 

[1] NIST, Mat Measurement Sci Div, Gaithersburg, MD 20899 USA

[2] Theiss Res, La Jolla, CA 92037 USA

[3] Univ Grenoble Alpes, LETI, CEA, F-38000 Grenoble, France

[4] European Commiss, Joint Res Ctr, Ispra, Italy

关键词: Field flow fractionation;    Liposome;    Complex drug;    Particle size;    Physical-chemical characterization;    Method validation;    Standardization;    Regulatory;   

DOI  :  10.1016/j.jconrel.2020.01.049

来源: Elsevier

【 摘 要 】

Liposomal formulations for the treatment of cancer and other diseases are the most common form of nano-technology enabled pharmaceuticals (NEPs) submitted for market approval and in clinical application today. The accurate characterization of their physical-chemical properties is a key requirement; in particular, size, size distribution, shape, and physical-chemical stability are key among properties that regulators identify as critical quality attributes. Here we develop and validate an optimized method, based on multi-detector asymmetrical-flow field flow fractionation (MD-AF4) to accurately and reproducibly separate liposomal drug formulations into their component populations and to characterize their associated size and size distribution, whether monomodal or polymodal in nature. In addition, the results show that the method is suitable to measure liposomes in the presence of serum proteins and can yield information on the shape and physical stability of the structures. The optimized MD-AF4 based method has been validated across different instrument platforms, three laboratories, and multiple drug formulations following a comprehensive analysis of factors that influence the fractionation process and subsequent physical characterization. Interlaboratory reproducibility and intra-laboratory precision were evaluated, identifying sources of bias and establishing criteria for the acceptance of results. This method meets a documented high priority need in regulatory science as applied to NEPs such as Doxil and can be adapted to the measurement of other NEP forms (such as lipid nanoparticle therapeutics) with some modifications. Overall, this method will help speed up development of NEPS, and facilitate their regulatory review, ultimately leading to faster translation of innovative concepts from the bench to the clinic. Additionally, the approach used in this work (based on international collaboration between leading non-regulatory institutions) can be replicated to address other identified gaps in the analytical characterization of various classes of NEPs. Finally, a plan exists to pursue more extended interlaboratory validation studies to advance this method to a consensus international standard.

【 授权许可】

Free